Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial

BACKGROUND: Empagliflozin slowed the progression of CKD in patients with type 2 diabetes and cardiovascular disease in the EMPA-REG OUTCOME Trial. In a prespecified statistical approach, we assessed treatment differences in kidney function by analyzing slopes of eGFR changes. METHODS: Participants (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Soc Nephrol
Main Authors: Wanner, Christoph, Heerspink, Hiddo J.L., Zinman, Bernard, Inzucchi, Silvio E., Koitka-Weber, Audrey, Mattheus, Michaela, Hantel, Stefan, Woerle, Hans-Juergen, Broedl, Uli C., von Eynatten, Maximilian, Groop, Per-Henrik
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Nephrology 2018
Assuntos:
Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6218863/
https://ncbi.nlm.nih.gov/pubmed/30314978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2018010103
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados